EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY-NC 4.0

Rebound Growth of Infantile Hemangiomas after Propranolol versus Atenolol Treatment: A Retrospective Study

Shoham Baruch, Dan Ben Amitai, Rivka Friedland

Dermatology · 11.11.2024 · 1-6

DOI: 10.1159/000542001 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Dermatology, online erschienen am 11.11.2024. Verfasst von Shoham Baruch und 2 weiteren Autor:innen. Beteiligte Einrichtung: Pediatric Dermatology Unit, Schneider Children's Medical Center of Israel, Petah Tikva, Israel, shoham88@gmail.com. Hauptthemen laut MEDLINE: Atenolol, Propranolol. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Propranolol is the first-line treatment for complicated infantile hemangioma (IH). Rebound growth following propranolol discontinuation is reported in 6–25% of patients. Atenolol is considered an effective alternative to propranolol. We aimed to compare the incidence of IH rebound growth following discontinuation of atenolol and propranolol and to identify associated risk factors.

Methods

We reviewed the medical records of all the patients diagnosed with IH and treated with oral propranolol or atenolol during 2009–2019 in our tertiary center. Inclusion criteria were completion of at least 3 months of initial treatment and at least 3 months of follow-up after discontinuation of initial treatment.

Results

Of 445 patients in total, 267 (60%) were treated with propranolol and 178 (40%) with atenolol. The incidence of rebound growth was similar between the groups: 59 (22.1%) and 40 (22.5%), respectively. Patients treated with atenolol required a shorter duration of treatment after rebound growth until growth arrest (9.41 ± 5.61 vs. 14.79 ± 10.02 months, p < 0.001). For the patients who initiated atenolol before the age of 5 months, the adjusted odds ratio (aOR) for regrowth was 0.6 (95% CI: 0.33–1.08). As duration of treatment increased, the risk of rebound growth increased; the aOR was 1.24 (95% CI: 1.10–1.38). No other significant risk factors for rebound growth were identified.

Conclusions

The incidence of rebound growth was similar following treatment with two oral β-receptor blockers. Treatment initiation after the age of 5 months and long duration of treatment may increase the risk for regrowth. These findings should be further investigated as they may impact clinical decisions on treating IH.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AtenololPropranololHumansRetrospective StudiesFemaleMaleInfantHemangiomaSkin NeoplasmsAdrenergic beta-AntagonistsRisk FactorsInfant, Newborn

Stichwörter der Autor:innen

Adrenergic beta-agonistsHemangiomaInfantsReboundRegrowth

Substanzen

AtenololPropranololAdrenergic beta-Antagonists

Autor:innen und Institutionen

  • Pediatric Dermatology Unit, Schneider Children's Medical Center of Israel, Petah Tikva, Israel, shoham88@gmail.com.
  • Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, shoham88@gmail.com.
  • Pediatric Dermatology Unit, Schneider Children's Medical Center of Israel, Petah Tikva, Israel.
  • Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Zitieren

APA

Baruch, S., Ben Amitai, D., & Friedland, R. (2024). Rebound Growth of Infantile Hemangiomas after Propranolol versus Atenolol Treatment: A Retrospective Study. Dermatology, 1-6. https://doi.org/10.1159/000542001

Vancouver

Baruch S, Ben Amitai D, Friedland R. Rebound Growth of Infantile Hemangiomas after Propranolol versus Atenolol Treatment: A Retrospective Study. Dermatology. 2024:1-6. doi:10.1159/000542001

BibTeX
@article{Baruch2024,
  author = {Baruch, Shoham and Ben Amitai, Dan and Friedland, Rivka},
  title = {Rebound Growth of Infantile Hemangiomas after Propranolol versus Atenolol Treatment: A Retrospective Study},
  journal = {Dermatology},
  year = {2024},
  pages = {1--6},
  doi = {10.1159/000542001}
}
Kostenlos starten →